Supplement



Supplement

Table 1. The EGFR Mutation Patterns of the 52 Non-Small Cell Lung Cancer Patients

| | | |Number of Patients |

|Group |Involved Exons |Mutation patterns (a.a. sequence) | |

|Exon 19 del |19 |del E746-A750 |20 |

| |19 |del L747_T751 |2 |

| |19 |delE746_S752insD |2 |

|L858R |21 |L858R |17 |

|Others |20 |D761_E762insEAFQ |1 |

| |20 |S768_D770dup |1 |

| |21 |L861Q |1 |

| |18 & 20 |G719S + S768I |1 |

| |18 & 21 |G719A + L861Q |1 |

| |18 & 21 |E709G + L858R |1 |

| |19 & 20 |delE746_T751insA + V769M |1 |

| |19 & 21 |V738F + L858R |1 |

| |19 & 21 |I744M + L858R |1 |

| |21 & 21 |L838V + L858R |1 |

| |21 & 21 |L833V + H835L |1 |

a.a., amino acid; del, deletion.

Supplement

Table 2. Univariate and Multivariate Survival Analyses of 55 Squamous Cell Carcinoma Patients

| |Death( |Median survival (month)| | | | |

|Variables |alive |[95% CI] |p valuea |RRb [95% CI] (p-value) |3-yearc (p-value) |5-yeard (p) |

|Year group |1 |26/ 7 |23.5 [17.7, 58.0] | |1 |0.424 (---) |0.333 (---) |

| |2 |12/10 |59.0 [28.5, ----] |0.1440 |0.11 [0.02,0.46] (0.0027) |0.591 (0.2177) |0.500 (0.2124) |

|Gender |F |4 / 1 |20.0 [1.9, ----] | |1 |0.200 (---) |0.200 (---) |

| |M |34/16 |44.8 [28.0, 76.7] |0.3207 |0.06 [0.01,0.52] (0.0112) |0.520 (0.2909) |0.420 (0.4148) |

|Age |=65 |22/ 6 |26.6 [15.6,67.5] |0.0976 |7.11 [2.00,25.24] (0.0024) |0.393 (0.1473) |0.357 (0.5123) |

|Stage |I |17/11 |62.7 [34.3, ----] | |1 |0.643 (---) |0.500 (---) |

| |II |6 / 2 |24.7 [16.2, 67.9] |0.2116 |2.85 [0.68,11.91] (0.1522) |0.375 (0.2591) |0.375 (0.5604) |

| |IIIA |15/ 4 |23.5 [4.8, 44.4] |0.0295 |15.85 [3.40,73.94](0.0004) |0.316 (0.0520) |0.263 (0.1334) |

|Smoking |(-) |10/ 7 |67.5 [30.8,104.7] | |1 |0.647 (---) |0.529 (---) |

|statusΔ |(+) |23/ 7 |28.3 [15.6,67.9] |0.1536 |9.82[2.35,41.12] (0.0018) |0.400 (0.0932) |0.333 (0.1802) |

|CISHΔ |(-) |20/11 |49.1 [28.0,104.7] | |1 |0.548 (---) |0.419 (---) |

| |(+) |3 / 2 |67.5 [ 8.5, --- ] |0.6614 |0.31 [0.07,1.33] (0.1142) |0.600 (0.8207) |0.600 (0.3948) |

|KRAS mutationΔ |(-) |35/16 |35.6 [23.5, 76.7] | |1 |0.490 (---) |0.412 (---) |

| |(+) |1/ 0 |21.0 [----, ----] |0.3648 |0.98 [0.09,11.41] (0.9896) |0.00 0(---) (*) |0.000 (---)(*) |

a: p-value from the log-rank test.

b: relative risk estimated adjusted for other variables using Cox PH model.

C: 3 year overall survival rate %

d: 5 year overall survival rate %

Δ: There are 8, 19, and 3 patients with no data at the smoking status, CISH, and KRAS mutation variables, respectively.

Supplement

Table 3. Univariate and Multivariate Survival Analyses of 97 Adenocarcinoma Patients

| |Death( |Median survival (month) | | | | |

|Variables |alive |[95% CI] |p valuea |RRb [95% CI] (p-value) |3-yearc (p-value) |5-yeard (p) |

|Year group |1 |24/ 6 |24.5 [16.2, 54.7] | |1 |0.400 (---) |0.300 (---) |

| |2 |32/35 |88.6 [42.6, 88.6] |0.0162 |0.30[0.13,0.66] (0.0029) |0.687 (0.0232) |0.536 (0.0542) |

|Gender |Female |27/18 |56.2 [38.0, 121.9] | |1 |0.644 (---) |0.467 (---) |

| |Male |29/23 |51.9 [26.2, ----] |0.9209 |0.97[0.46,2.04] (0.9311) |0.558 (0.3877) |0.460 (0.9451) |

|Age |=65 |30/16 |28.9 [18.0, 62.4] |0.0384 |3.42 [1.61,7.29] (0.0014) |0.457 (0.0111) |0.370 (0.0926) |

|Stage |I |26/30 |88.6 [43.3, --- ] | |1 |0.696 (---) |0.589 (---) |

| |II |9/ 4 |31.5 [18.0,125.8] |0.0873 |1.75 [0.64,4.85] (0.2787) |0.462 (0.1892) |0.385 (0.2476) |

| |IIIA |21/ 7 |25.9 [11.8, 56.2] |0.0019 |3.33 [1.53,7.26] (0.0025) |0.464 (0.0670) |0.250 (0.0132) |

|Smoking |(-) |40/33 |62.4 [40.8,125.8] | |1 |0.658 (---) |0.506 (---) |

|statusΔ |(+) |13/ 7 |20.6 [11.8,----] |0.1159 |1.19 [0.47,2.99] (0.7161) |0.450 (0.1456) |0.350 (0.2584) |

|CISHΔ |(-) |21/17 |56.7 [23.2, ----] | |1 |0.579 (---) |0.499 (---) |

| |(+) |23/20 |56.2 [38.0, --- ] |0.9268 |1.41 [0.59,3.38] (0.4355) |0.651 (0.5097) |0.488 (0.9213) |

|KRAS mutationΔ |(-) |50/36 |52.0 [38.0,125.8] | | |0.605 (---) |0.452 (---) |

| |(+) |4/ 2 |53.30 [11.4, 88.6] |0.5526 |0.94 [0.30,2.98] (0.9171) |0.500 (0.6479) |0.500 (0.8124) |

|EGFR |Wt L858R |25/18 |40.1 [18.0, ----] | | |0.512 (---) |0.465 (---) |

|MutationΔ |19 Del |9/ 8 |62.4 [38.0, ---] |0.4989 |0.31 [0.10,0.98] (0.0452) |0.765 (0.0453) |0.529 (0.6468) |

| |others |13/ 9 |51.9 [29.5, ---] |0.6660 |0.49 [0.18,1.32] (0.1572) |0.636 (0.3231) |0.455 (0.9392) |

| | |7/ 3 |56.2 [27.4, ---] |0.8505 |0.86 [0.27,2.69] (0.7915) |0.600 (0.5946) |0.300 (0.3901) |

|EGFR |Wt L858R |24/17 |29.5 [17.1, ----] | | |0.488(---) |0.439(---) |

|Mutation( |19 Del |6/ 5 |62.4 [28.3, ---] |0.5492 |0.38 [0.09,1.63](0.1939) |0.727(0.1029) |0.546(0.5044) |

| |others |12/ 6 |44.4 [28.0,125.8] |0.9140 |0.59 [0.19,1.86](0.3681) |0.556(0.6219) |0.389(0.7253) |

| | |6/ 3 |56.2 [27.4, ---] |0.9758 |1.24 [0.33,4.63](0.7529) |0.556(0.6996) |0.333(0.5833) |

a: p-value from the log-rank test.

b: relative risk estimated adjusted for other variables using Cox PH model.

C: 3 year overall survival rate %

d: 5 year overall survival rate %

Δ: There are 4, 16, 5, and 5 patients with no data at the smoking status, CISH, KRAS, and EGFR mutation variables, respectively.

(: Five patients with no data at the EGFR mutation variable, and 13 patients who had received TKI treatment for tumor recurrence were not included .

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download